KDR and neoplasm: Treatment strategies include monoclonal antibodies like bevacizumab, which specifically bind to VEGF-A, as well as small molecule multi-target inhibitors such as sorafenib and sunitinib, which exert anti-tumor effects by targeting VEGFR and other tyrosine kinases.